SenzaGen AB (STO:SENZA)

Market Cap	178.79M +36.5%
Revenue (ttm)	57.97M +0.5%
Net Income	-11.59M
EPS	-0.39
Shares Out	32.51M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	25,440
Average Volume	21,899
Open	5.60
Previous Close	5.50
Day's Range	5.32 - 5.68
52-Week Range	4.49 - 6.84
Beta	0.50
RSI	56.17
Earnings Date	May 12, 2026

About SenzaGen AB

SenzaGen AB provides non-animal tests for assessing allergenicity. The company offers GARD skin OECD 442E, GARD skin dose-response, GARD skin medical device; and GARD air, a respiratory sensitization assessment. It also provides biological evaluation, in vitro biocompatibility testing, cytotoxicity, irritation, and skin sensitization medical device services; advisory services for medical devices; and substance based medical devices. In addition, the company offers regulatory toxicity testing services, including skin corrosion, skin irritation, ...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 2010
• Employees: 36
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: SENZA

Financial Performance

In 2025, SenzaGen AB's revenue was 57.97 million, an increase of 0.48% compared to the previous year's 57.70 million. Losses were -11.59 million, -35.09% less than in 2024.